Epidemiology of Community Acquired Pneumonia in North Israel

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2006 by HaEmek Medical Center, Israel.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00390819
First received: October 19, 2006
Last updated: NA
Last verified: October 2006
History: No changes posted

October 19, 2006
October 19, 2006
November 2006
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Epidemiology of Community Acquired Pneumonia in North Israel
Epidemiology of Community Acquired Pneumonia in North Israel

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality and is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen.

Aim of study: To identify common pathogens causing CAP in hospitalized patients in north Israel.

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality.

CAP is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen.

CAP is divided to two principal groups: Bacterial CAP and Atypical CAP. Since pathogens are different, treatment approach is also different. The main obstacle is absence of adequate diagnostic immediate and cheap tools to enable identifying pathogen and hence treatment is not always appropriate. Giving the right therapy at the right time is of major importance since early start of correct treatment is linked to morbidity and mortality of patients. For prescribing appropriate empiric therapy, knowing the epidemiology of CAP, i.e. the frequent causing pathogens according to age groups and other demographic characteristics, is essential.

Unfortunately, except one study conducted 10 years ago by Dr. Liberman from Soroka Medical Center, there is no characteristic information regarding causing pathogens. Lacking this data, might result in selecting inadequate treatment.

Material & Methods:

We should enroll about 300 patients hospitalized in Ha'Emek Medical Center with the diagnosis of CAP, in order to make the study results statistically significant.

In addition to demographic and clinical data, following tests will be performed:

  1. Blood cultures
  2. Sputum
  3. PCR - throat culture to the following pathogens:

    • Mycoplasma pneumoniae
    • Chlamydia pneumoniae
    • Legionella
    • Adenovirus
    • Influenza A
    • Influenza B
    • RSV
    • Metapneumovirus
    • Parainfluenza
    • Pneumococcal antigen in urine
Observational
Observational Model: Defined Population
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
Community Acquired Pneumonia
Not Provided
Not Provided
Porath A, Schlaeffer F, Lieberman D. The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect. 1997 Jan;34(1):41-8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
100
Not Provided
Not Provided

Inclusion Criteria:

  • Community acquired pneumonia
  • Hospitalization

Exclusion Criteria:

  • Immunocompromised patients
  • Patients under chemotherapy treatment
  • Patients under steroids treament
Both
18 Years and older
No
Contact: Fahmi Shibli, M.D. 972-4-6494000 ext 4347 fahmi_shibli@yahoo.ie
Israel
 
NCT00390819
131074
Not Provided
Not Provided
HaEmek Medical Center, Israel
Not Provided
Principal Investigator: Fahmi Shibli, M.D. Ha'Emek Medical Center, Afula, Israel
HaEmek Medical Center, Israel
October 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP